New research finds that the costs of diabetes care and lost productivity due to the condition totaled $322 billion in 2012. Also, new warnings about hookah smoke.
A German federal court has ruled that the liquids contained in e-cigarettes aren't medicinal...
The average cost of developing an approved therapy is around $4.3 billion dollars for companies...
The Cystic Fibrosis Foundation says it has sold royalty rights worth $3.3B for innovative drugs...
Some low-cost generic drugs that have helped restrain health care costs for decades are seeing unexpected price spikes of up to 8,000 percent, prompting a backlash from patients, pharmacists and now Washington lawmakers.
A new report by the McKinsey Global Institute says that the global cost of obesity has risen to $2 trillion annually — nearly as much as smoking or the combined impact of armed violence, war and terrorism.
Apellis Pharmaceuticals has entered into an agreement to acquire Potentia Pharmaceuticals. As part of the acquisition agreement, Apellis obtained the necessary intellectual property rights to develop its complement inhibitor drug compound (APL-2) in ophthalmology and plans its first clinical trial in dry age-related macular degeneration.
Shire has announced plans to relocate over 500 positions to Massachusetts from its Chesterbrook, Pennsylvania site and establish Lexington, Massachusetts as the company's U.S. operational headquarters. The transition is a continuation of the company's 'One Shire' efficiency program and will streamline business globally through two principal locations - Massachusetts and Switzerland.
The pharmaceutical market is beginning to show signs of stability, with a review of 30 leading companies highlighting combined revenues of $718.7 billion in 2013, down just 0.2% from 2012, according to research and consulting firm GlobalData.
Developing a new prescription medicine that gains marketing approval, a process often lasting longer than a decade, is estimated to cost $2,558 million, according to a new study by the Tufts Center for the Study of Drug Development.
Knight Therapeutics today announced the sale of its Neglected Tropical Disease Priority Review Voucher ("PRV"). Knight will receive US$125 million in cash from Gilead Sciences, Inc. in exchange for the PRV.
According to Joshua Owide, GlobalData’s Director of Healthcare Industry Dynamics, "The integration of Allergan and Forest will help grow Actavis to a $22 billion healthcare company in 2015. This is a dramatic elevation from its $8.7 billion revenues recorded in 2013, the year in which Actavis completed the $5 billion acquisition of Warner Chilcott."
Zoetis today announced that its Board of Directors has authorized a $500 million share repurchase program as part of its capital allocation plans. The shares are expected to be repurchased at the discretion of management, depending on market conditions and business needs.
To help people harmed by shots, Congress created the National Vaccine Injury Compensation Program. Government doctors and lawyers review claims. If they believe it is more likely than not that a vaccine — and not something else — caused the injury, they tap a $3.5 billion fund to pay for future care and lost wages. That fund is replenished by a 75-cent tax on each vaccine.
Actavis will pay $66 billion to buy fellow drugmaker Allergan in a deal that could finally stop a months-long takeover push from Valeant Pharmaceuticals for the Botox maker.
Zoetis today announced an agreement to purchase animal health assets of Abbott for a purchase price of $255 million. Abbott Animal Health is a companion animal health business focused on the veterinary surgical suite.
A proposed global emergency fund to contain the next Ebola outbreak would also provide an incentive for drug companies to develop vaccines to fight other future pandemics, World Bank President Jim Yong Kim said Friday.
Shares of Allergan jumped in premarket trading Monday after several reports surfaced over the weekend that specialty drugmaker Actavis was preparing to buy the maker of Botox, which is embroiled in a takeover battle with Valeant Pharmaceuticals.
Zoetis Inc. said Friday that it has adopted a one-year shareholder rights plan. These plans, often known as "poison pills", are intended to fight off hostile takeovers. Zoetis said the plan would enable existing shareholders a right to buy preferred stock if a person or group acquires at least 15 percent of the company's stock and tries to buy more.
Geron Corp. could get more than $900 million from a deal to develop its blood disorder drug imetelstat with a unit of Johnson & Johnson. Geron said Janssen Biotech agreed to pay it $35 million upfront.
Activist investor William Ackman has taken a roughly $2 billion stake in Zoetis and could push the animal-health company to sell itself to a larger drug maker.
Golden Gate Capital today announced that it has entered into a definitive agreement to acquire ANGUS Chemical Company from The Dow Chemical Company for $1.215 billion.
The family of Ebola victim Thomas Eric Duncan has reached a settlement with Dallas Presbyterian Hospital. Also, the last remaining Ebola patient in the U.S., Dr. Craig Spencer, was released from the hospital.
Intarcia Therapeutics has announced the successful start of a strategic partnership with Servier outside the United States and Japan, to develop and commercialize ITCA 650, Intarcia's phase 3 investigational therapy for the treatment of type 2 diabetes.
Allergan today announced that its Board of Directors has approved amendments to the company’s bylaws that streamline the process associated with calling a special meeting of stockholders. The Board determined to amend the bylaws after meetings with many of the Company’s major stockholders and other governance organizations to solicit their input and perspectives.
Zoetis Inc. shares jumped Tuesday on a report that activist investor William Ackman has taken a stake in the animal health company and could push for its sale. The company said that it did receive a call from Ackman indicating that the firm has made an investment in Zoetis.
Biologics will play an influential role in shaping the future of cardiovascular (CV) drug treatment, as these and other emerging therapies will compete for patients who cannot tolerate statins, or for whom statin therapy alone is insufficient, according to an analyst with research and consulting firm GlobalData.
Shares of Orexigen Therapeutics jumped Monday after the company said a European Union review of its weight loss drug Contrave, which was approved in the U.S. in September, is progressing on schedule.
A new study shows that the cost for treating skin cancer has increased by 126 percent in recent years. Also, new research on obesity in children.
- Page 1